One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
A vaccination update for rheumatologists—SARS-CoV-2, influenza and herpes zoster
Peter K. K. Wong,Manjari Lahiri,David Chien Lye,Douglas Johnson,Patrick G. P. Charles,
doi : 10.1111/1756-185X.14179
Volume 24, Issue 8 p. 979-983
Microbiome and osteoarthritis: New insights from animal and human studies
Tze Chin Tan,Timothy Kit Yeong Chong,Andrea Hsiu Ling Low,Ying Ying Leung,
doi : 10.1111/1756-185X.14123
Volume 24, Issue 8 p. 984-1003
Osteoarthritis (OA) is a common cause of disability, especially among the elderly. With an ageing and increasingly obese population, OA will become more prevalent. Obesity and metabolic syndrome are risk factors for OA and have been implicated in its pathogenesis. The gut microbiome may shed light on this possible common pathogenesis. Recent animal and human studies have gained important insights into the relationship between OA, obesity, and the gut microbiome. Animal studies have demonstrated links between obesity and increased severity of OA and altered gut microbial DNA profile. Use of prebiotics and probiotics in animal trials provides proof-of-concept that interventional options to the gut microbiome can modulate the progression of OA favorably. Current evidence in human studies is limited. Shifts in gut microbial profile and reduced gut microbial diversity have been associated with people with OA, as well as blood and synovial fluid lipopolysaccharide endotoxemia. Linkages between microbiome dysbiosis and host responses may help in the understanding of OA pathogenesis and the discovery of therapeutic targets. This narrative review provides a summary of up-to-date animal and human studies on the gut microbiome and its link with OA.
Coronary (peri)-arteritis in patients with IgG4-related disease: A case series from the Central Anatolia Region of Turkey
Gozde Kubra Yardimci,Selin Ardali Duzgun,Ertugrul Cagri Bolek,Levent Kilic,Ugur Canpolat,Tuncay Hazirolan,Kudret Aytemir,Omer Karadag,
doi : 10.1111/1756-185X.14153
Volume 24, Issue 8 p. 1004-1013
Immunoglobulin G4-related disease (IgG4-RD) is a newly recognized fibro-inflammatory disease which affects many systems, as well as the cardiovascular system. Identifying the coronary involvement like periaortitis, coronary periarteritis and pericarditis is important, as they often cause unfavorable outcomes.
Exercise capacity in axial spondyloarthritis and associated factors: A cross-sectional controlled study
Ebru K?seo?lu Tohma,Zafer Günendi,?zden ?zyemi?çi Ta?k?ran,G?nen Mengi,Nesrin Demirsoy,Nihal Ta?,
doi : 10.1111/1756-185X.14155
Volume 24, Issue 8 p. 1014-1023
To examine the associations between exercise capacity (EC), cardiovascular (CV) risk factors and disease-related variables in axial spondyloarthritis (AxSpA) patients.
Downregulation of miR-98-5p expression induces interleukin-6 expression in rheumatoid fibroblast-like synoviocytes
Shujun Wang,Qin Geng,Hongju Zhang,Qing Du,Qiaofeng Wei,Yanhui Cui,Xiuying Zhang,Min Yuan,
doi : 10.1111/1756-185X.14160
Volume 24, Issue 8 p. 1024-1031
The increased level of interleukin-6 (IL-6) plays a significant role in the pathogenesis of rheumatoid arthritis (RA). Specific blockade of IL-6 or its receptor has been used successfully in treating RA. MicroRNAs can regulate gene expression and act as regulators of target genes. Manipulation of specific microRNAs provides a novel therapeutic strategy for treating/preventing diseases. This study explored the role of miR-98-5p in the regulation of IL-6 expression in rheumatoid fibroblast-like synoviocytes (RA-FLSs).
Circulating CD4+ FoxP3– CXCR5– CXCR3+ PD-1hi cells are elevated in active rheumatoid arthritis and reflect the severity of the disease
Lei Zhao,Zhenxue Li,Xingyue Zeng,Changsheng Xia,Lijuan Xu,Qinzhu Xu,Ying Song,Chen Liu,
doi : 10.1111/1756-185X.14170
Volume 24, Issue 8 p. 1032-1039
To examine the expression and clinical significance of circulating CD4+ FoxP3– CXCR5– CXCR3+ PD-1hi cells in rheumatoid arthritis (RA).
Turkish version of modified Hand Mobility in Scleroderma test: A translation and validation study
Serdar Kaymaz,Ugur Karasu,Hakan Alkan,Veli Cobankara,
doi : 10.1111/1756-185X.14162
Volume 24, Issue 8 p. 1040-1046
Hand Mobility in Scleroderma (HAMIS) is a hand function test used to determine the degree of dysfunction of hand movements. The Modified Hand Mobility in Scleroderma (mHAMIS), on the other hand, was developed later and consists of 4 items. The aim of this study was to determine the reliability and validity of mHAMIS.
Invalidation in fibromyalgia and rheumatoid arthritis and its effect on quality of life in Indian patients
Gurmeet Singh,Abdul Hamid,
doi : 10.1111/1756-185X.14163
Volume 24, Issue 8 p. 1047-1052
Fibromyalgia (FM) and rheumatoid arthritis (RA) patients face invalidation in the form of “discounting” and “lack of understanding”. Invalidation can have effects on the quality of life (QoL) in these patients. We planned this study to look for invalidation in FM and RA Indian patients and see the correlation between invalidation and QoL.
Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long-term and low-dose glucocorticoid
Kyung-Ann Lee,JongSun Kim,Hyun-joo Kim,Hyun-Sook Kim,
doi : 10.1111/1756-185X.14164
Volume 24, Issue 8 p. 1053-1060
To evaluate the ability of the trabecular bone score (TBS) to discriminate vertebral fracture (VF) and fragility fracture (FF) in patients with chronic inflammatory rheumatic diseases on long-term and low-dose glucocorticoid (GC) treatment and those without exposure to GC.
Interval between symptom onset and diagnosis among patients with autoimmune rheumatic diseases in a multi-ethnic Asian population
Ling Xiang,Andrea Hsiu Ling Low,Ying Ying Leung,Warren Fong,Mihir Gandhi,Sungwon Yoon,Tang Ching Lau,Dow Rhoon Koh,Julian Thumboo,
doi : 10.1111/1756-185X.14165
Volume 24, Issue 8 p. 1061-1070
The interval between symptom onset and diagnosis (pre-diagnosis interval) can at times be longer than is ideal in patients with autoimmune rheumatic diseases (ARDs). In this study, we aimed to characterize this interval and to identify its associated factors.
Development and validation of a Behçet's Disease Damage Index for adults with BD: An Explicit, Composite and Rated (ECR) tool
Tamer A. Gheita,Nevin Hammam,Samar M. Fawzy,Eiman Abd El-Latif,Iman I. El-Gazzar,Nermeen Samy,Dina H. El-Hammady,Rasha Abdel Noor,Emad El-Shebini,Amany R. El-Najjar,Nahla N. Eesa,Mohamed N. Salem,Soha E. Ibrahim,Dina F. El-Essawi,Ahmed M. Elsaman,Soha Senara,Hanan M. Fathi,Rehab A. Sallam,Rawhya R. El Shereef,Mervat I. Abd Elazeem,Rasha M. Fawzy,Noha M. Khalil,Dina Shahin,Hanan M. El-Saadany,Marwa ElKhalifa,Samah I. Nasef,Ahmed M. Abdalla,Nermeen Noshy,Emtethal A. Said,Ehab Saad,Abdel Hafeez Moshrif,Amira T. El-Shanawany,Yousra H. Abdel-Fattah,Hala A. Raafat,Hossam M. Khalil,the Egyptian College of Rheumatology-Behçet's Disease Study Group (ECR-BDSG)
doi : 10.1111/1756-185X.14166
Volume 24, Issue 8 p. 1071-1079
Behçet's disease (BD) is a chronic multisystem variable vessel vasculitis. Disease damage is irreversible and permanent. Validated tools evaluating damage are limited. Enhancements in the clinical treatment of vasculitis will take place from the development of refined and exclusive indices for individual vasculitic syndromes including BD and attempting their international validation.
Familial aggregation of juvenile idiopathic arthritis with other autoimmune diseases: Impact on clinical characteristics, disease activity status and disease damage
Sulaiman M. Al-Mayouf,Abeer Alrasheedi,Iman Almsellati,Soad Hashad,Khulood Khawaja,Reem Abdwani,Samia AlHashim,Mohammed Muzaffer,Hala Lotfy,Nora Almutairi,
doi : 10.1111/1756-185X.14167
Volume 24, Issue 8 p. 1080-1085
To evaluate the impact of family history of autoimmune diseases (FHADs) on the clinical characteristics and outcome of juvenile idiopathic arthritis (JIA).
Sj?gren’s syndrome complicated with membranous nephropathy, a cause or coincidence?
Ruiying Chen,Jia Wang,Qionghong Xie,Jun Xue,Chuanming Hao,
doi : 10.1111/1756-185X.14168
Volume 24, Issue 8 p. 1086-1094
Sj?gren's syndrome (SS) has been a well-documented cause of secondary membranous nephropathy (MN); however, the prevalence is quite low. Since primary MN is also a common disease in middle age, whether MN is secondary to SS or just coincidence remains uncertain. The detection of phospholipase A2 receptor (PLA2R), which is most often positive in idiopathic MN, has been rarely reported in such cases.
Vale Dr Christina Ann Boros (1966-2021)
Davinder Singh-Grewal
doi : 10.1111/1756-185X.14181
Volume 24, Issue 8 p. 1095-1096
Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global rheumatology alliance registry
doi : 10.1111/1756-185X.14119
Volume 24, Issue 8 p. 1097-1097
